BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30177129)

  • 21. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
    Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thoracic presentations of posttransplant lymphoproliferative disorders.
    Halkos ME; Miller JI; Mann KP; Miller DL; Gal AA
    Chest; 2004 Dec; 126(6):2013-20. PubMed ID: 15596707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
    Arita H; Izumoto S; Kinoshita M; Okita Y; Hashimoto N; Fujita T; Ichimaru N; Takahara S; Yoshimine T
    Neurol Med Chir (Tokyo); 2010; 50(12):1079-83. PubMed ID: 21206182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early post-transplant lymphoproliferative disorder – Case of fatal lymphoma after kidney transplantation.
    Laušević M; Markovic-Lipkovski J; Terzić T; Jovanović N; Milinković M; Naumović R
    Srp Arh Celok Lek; 2016; 144(5-6):325-8. PubMed ID: 29648755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Native kidney posttransplant lymphoproliferative disorder in a renal transplant recipient.
    Chandra A; Kaul A; Aggarwal V; Srivastava D
    Saudi J Kidney Dis Transpl; 2017; 28(4):942-944. PubMed ID: 28748904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy.
    Ryu HJ; Hahn JS; Kim YS; Park K; Yang WI; Lee JD
    Yonsei Med J; 2004 Jun; 45(3):527-32. PubMed ID: 15227742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmacytoma-like Posttransplant Lymphoproliferative Disorder in a Pediatric Heart Transplant Recipient.
    Proctor Short SR; Cook SL; Kim AS; Lamour JM; Lowe EJ; Petersen WC
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):e71-4. PubMed ID: 26859193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience.
    Saadat A; Einollahi B; Ahmadzad-Asl MA; Moradi M; Nafar M; Pourfarziani V; Firoozan A; Porrezagholi F; Davoudi F
    Transplant Proc; 2007 May; 39(4):1071-3. PubMed ID: 17524894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN; Thomas CP; Hohl RJ; Syrbu SI; Stone MS; Wanat KA
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.